Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial-Reference-Cited by-同舟云学术

Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial

Published:2022-06 Issue:6 Volume:22 Page:857-866
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Evans Thomas G,Bussey Louise,Eagling-Vose Elizabeth,Rutkowski Kathryn,Ellis Chris,Argent Chris,Griffin Paul,Kim Joshua,Thackwray Susan,Shakib Sepehr,Doughty Julia,Gillies John,Wu Jian,Druce Julian,Pryor Melinda,Gilbert Sarah

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference36 articles.

1. The annual impact of seasonal influenza in the US: measuring disease burden and costs;Molinari;Vaccine,2007

2. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies;Belongia;Lancet Infect Dis,2016

3. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis;Osterholm;Lancet Infect Dis,2012

4. Control of influenza virus infection by immunity to conserved viral features;Epstein;Expert Rev Anti Infect Ther,2003

5. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus;Schulman;J Bacteriol,1965

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mosaic neuraminidase-based vaccine induces antigen-specific T cell responses against homologous and heterologous influenza viruses;Antiviral Research;2024-10

2. Enhancing the use of T cells as a universal preventive measure against H3N2 influenza: Mechanism and implications;Health Science Reports;2024-08

3. Integrated epigenomic exposure signature discovery;Epigenomics;2024-07-17

4. Assessment of CD8+ T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 study;The Lancet Microbe;2024-07

5. Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65–85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial;The Lancet Infectious Diseases;2024-07